Other Clinical Trial - Antiretroviral Therapy & Inflammatory & Coagulation

Status Completed

Clinical Trial Summary

The aim of this study is to develop and follow a cohort of human immunodeficiency virus (HIV)-infected adults who are starting HIV drugs at health facilities in Kenya. Blood and urine samples will be collected from all participants in order to establish a sample bank of samples in order to further the understanding of the levels of inﬂammatory biomarkers and coagulation biomarkers in African patients and the effect of taking HIV drugs on these biomarkers. This study will enroll and follow 685 men and women who are starting HIV drugs and collect blood and urine specimens from them at 4 study visits. These samples will be frozen and stored for future testing related to inﬂammatory and coagulation biomarkers.

Clinical Trial Description

Biomarkers have been investigated as predictors of HIV disease progression, i.e. development of acquired immunodeficiency syndrome (AIDS) deﬁning diagnoses or death. There are limited data on the levels of these biomarkers among HIV-infected individuals in sub Saharan Africa and on the effect of antiretroviral therapy (ART) initiation on these levels. In addition, further work is needed to examine the association between such markers and various complications associated with HIV as well as mortality in sub Saharan Africa. The overall aim of this study is to develop a cohort of HIV-infected adults who are initiating ART at health facilities in Kenya and to establish a sample bank of plasma and urine samples in order to further the understanding of the levels of inﬂammatory biomarkers (IBM) and coagulation biomarkers (CBM) in African patients and the effect of ART initiation on these biomarkers. The study objectives are as follows:

- To recruit, establish and follow a cohort of HIV-infected individuals who are eligible for initiation of ART through 12 months

- To obtain blood and urine samples on all cohort participants at baseline, months 2, 6, and 12 for future HIV and related research

- To describe the demographic and disease characteristics of cohort participants and associations with various biomarkers ;

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Acquired Immunodeficiency Syndrome
AIDS (Acquired Immune Deficiency Syndrome)
HIV (Human Immunodeficiency Virus)
HIV Infections
Immunologic Deficiency Syndromes
Non-communicable Diseases (NCD)
Tuberculosis

Clinical Trial Details

NCT number	NCT02027480
Study type	Observational
Source	Columbia University
Contact
Status	Completed
Phase	N/A
Start date	March 2014
Completion date	October 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05738681` - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial	Phase 2/Phase 3
Recruiting	`NCT05526885` - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa	N/A
Completed	`NCT04369326` - Community Initiated Preventive Therapy for TB	N/A
Recruiting	`NCT04568967` - TB-CAPT EXULTANT - HIV	N/A
Completed	`NCT02337270` - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol	Phase 1
Not yet recruiting	`NCT06253715` - Shortened Regimen for Drug-susceptible TB in Children	Phase 3
Recruiting	`NCT04271397` - Immunological Biomarkers in Tuberculosis Management	N/A
Withdrawn	`NCT03639038` - Tuberculosis Diagnosis by Flow Cytometry
Completed	`NCT03199313` - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid	Phase 1
Recruiting	`NCT04975178` - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa	Phase 3
Completed	`NCT04463680` - Rifampin and the Contraceptive Implant	Phase 4
Completed	`NCT03973970` - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting	`NCT04230395` - Alcohol Reduction Among People With TB and HIV in India	N/A
Completed	`NCT04874948` - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment	Phase 1
Active, not recruiting	`NCT02906007` - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV	Phase 1/Phase 2
Not yet recruiting	`NCT05917210` - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda	N/A
Not yet recruiting	`NCT05845112` - Start Taking Action For TB Diagnosis
Not yet recruiting	`NCT06017843` - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding	N/A
Active, not recruiting	`NCT02715271` - Study of TB Lesions Obtained in Therapeutical Surgery
Completed	`NCT02781909` - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Antiretroviral Therapy and Inflammatory and Coagulation Biomarkers: iMACS Study — iMACS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms